IntroductionRemdesivir (RDV) and nirmatrelvir/ritonavir (NRM/RTV) are two antiviral agents for treating outpatient adults with mild to moderate symptomatic COVID-19 at high risk of developing a severe

NIAID Data Ecosystem10

The heterogeneity in the cost per case avoided with coxibs stratified by the number of major risk factors and exposure characteristics (with the cost per case avoided estimated for each individual prescription).

药物经济学评估

临床用药优化

#Each NSAID prescription was classified according to first-ever use, long gap (previous prescription at least 6 mo before), and short gap (previous prescription within the last 6 mo). The medication p

Figshare2015-12-02 更新10

Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/ .

药物经济学评估

心血管治疗成本分析

Incremental Costs, Revenues and Outcomes with PCSK9 (Per Patient. Health System’s and Payer’s Perspective) 1/.

NIAID Data Ecosystem30

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

药物经济学评估

类风湿关节炎治疗管理

Differences in healthcare resource utilization and direct medical costs of patients with rheumatoid arthritis (RA) before and after the use of multiple biologic agents-Switched.

Figshare2018-07-18 更新10

Unit cost of selections.

资源简介：

相关数据集